International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 21s, 2025
https://theaspd.com/index.php

Solid Lipid Nanoparticles As A Versatile Platform For Targeted And Controlled Drug Delivery

K. Sunil Kumar[1], S.Jeganath[1]
[1]Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology And Advanced Studies (VISTAS), Pallavaram, Chennai-600117, India.
*Corresponding author Email Id: jeganaths@gmail.com

Abstract
Solid lipid nanoparticles (SLNs) have emerged as a versatile nanocarrier platform for the targeted and controlled delivery of therapeutic agents. Comprising physiological lipids stabilized by surfactants, SLNs combine the advantages of conventional colloidal carriers such as liposomes and polymeric nanoparticles while overcoming their limitations related to stability, scalability, and toxicity. These submicron particles, typically in the range of 50–1000 nm, possess a solid lipid matrix at body temperature, enabling high drug encapsulation efficiency, controlled release, and protection of labile molecules against chemical degradation. Recent advances in SLN technology include surface modification for active targeting, hybrid systems incorporating polymers, and stimuli-responsive formulations triggered by pH, temperature, or enzymatic activity. SLNs have been successfully explored for oral, parenteral, pulmonary, ocular, and transdermal delivery of small molecules, peptides, proteins, and nucleic acids. Challenges such as limited drug loading, burst release, and lipid polymorphism remain, but emerging strategies such as nanostructured lipid carriers (NLCs), combinatorial lipid–polymer hybrids, and green manufacturing techniques are expanding their potential. This review provides a comprehensive overview of SLN design, formulation considerations, applications in targeted and controlled drug delivery, and future directions aimed at clinical translation.
Keywords: *Solid lipid nanoparticles; Targeted drug delivery; Controlled release; Nanostructured lipid carriers; Pharmaceutical nanotechnology.*

INTRODUCTION

Nanotechnology has become a transformative force in pharmaceutical sciences, enabling the design of delivery systems with precise control over drug release, biodistribution, and therapeutic activity. Within this landscape, solid lipid nanoparticles (SLNs) have emerged as a promising class of lipid-based nanocarriers that combine the advantages of traditional colloidal systems, such as emulsions and liposomes, with the structural stability and controlled release potential of polymeric nanoparticles. SLNs are typically composed of biocompatible and biodegradable lipids that remain in a solid state at both ambient and physiological temperatures, stabilized by surfactants or emulsifiers. Their particle size generally ranges from 50 to 1000 nm, and the solid lipid matrix allows for the encapsulation of both hydrophobic and certain hydrophilic drugs while protecting them from chemical degradation, enzymatic attack, and photolysis [1, 2].

The concept of SLNs was first introduced in the early 1990s as a second-generation lipid carrier system, intended to overcome the limitations of oil-in-water emulsions and liposomes, which often suffer from instability, low encapsulation efficiency, or high production costs. Compared to polymeric nanoparticles, SLNs avoid the use of synthetic polymers that may raise toxicity concerns, instead employing physiological lipids such as glyceryl behenate, stearic acid, cetyl palmitate, or tripalmitin, which are generally recognized as safe (GRAS). The lipid matrix not only offers sustained or controlled drug release but also provides a protective environment for labile molecules, thereby extending shelf-life and improving therapeutic performance [3].

Production techniques for SLNs, including high-pressure homogenization (hot and cold), microemulsion-based methods, solvent emulsification–evaporation, and ultrasonication, enable scalable manufacturing while offering flexibility in tailoring particle characteristics to specific therapeutic needs. The versatility of SLNs extends beyond simple drug encapsulation they can be surface-modified with polymers such as polyethylene glycol (PEG) to impart stealth properties, or conjugated with targeting ligands like antibodies, peptides, and aptamers to achieve active targeting of specific cells or tissues. This capability is particularly valuable in oncology, where selective delivery to tumor sites via the enhanced permeability and retention (EPR) effect can improve therapeutic index and reduce systemic toxicity. In addition to targeted delivery, SLNs are being increasingly explored for controlled release applications. By manipulating lipid crystallinity, polymorphic transitions, and particle surface characteristics, researchers

can modulate the release rate of encapsulated drugs, ensuring a sustained therapeutic effect and reducing dosing frequency. Moreover, their solid lipid matrix supports high physical stability, making them suitable for a range of administration routes including oral, intravenous, pulmonary, ocular, transdermal, and even intranasal delivery [4, 5].

Despite these advantages, SLNs face challenges such as limited drug loading capacity, potential burst release, and instability due to lipid polymorphism during storage. However, advancements such as nanostructured lipid carriers (NLCs), hybrid lipid–polymer systems, and stimuli-responsive SLNs are addressing these issues. The continuing evolution of SLN technology, coupled with advances in materials science, surface engineering, and green manufacturing processes, positions them as a versatile and sustainable platform in modern pharmaceutics [6]. This review explores the formulation considerations, applications in targeted and controlled drug delivery, current challenges, and future perspectives for SLNs, with an emphasis on their potential to bridge the gap between laboratory innovation and clinical translation.

Formulation Considerations

The successful design of solid lipid nanoparticles (SLNs) hinges on a careful balance of formulation components and processing parameters to achieve optimal stability, drug loading, and release profiles. At the core of SLNs is the lipid matrix, which must remain solid at both room and physiological temperatures to maintain the integrity of the nanoparticle and provide controlled drug release. Commonly used solid lipids include glyceryl behenate (Compritol® 888 ATO), glyceryl palmitostearate (Precirol® ATO 5), stearic acid, cetyl palmitate, and tripalmitin. The selection of lipid is guided by factors such as melting point, crystallinity, compatibility with the drug, and regulatory acceptance. Lipid crystallinity directly affects drug incorporation and release; a more ordered crystalline lattice may limit drug loading but enhances physical stability, while less ordered structures can accommodate higher drug loads but may risk expulsion during storage due to polymorphic transitions. Surfactants and co-surfactants play a crucial role in stabilizing SLNs by reducing the interfacial tension between the lipid and aqueous phases and preventing particle aggregation. Non-ionic surfactants such as polysorbates (Tween® 20, Tween® 80), poloxamers (Poloxamer 188, Poloxamer 407), and lecithin are preferred for their lower toxicity and biocompatibility. In certain cases, bile salts or ionic surfactants are incorporated to improve stability or drug loading. The surfactant concentration must be optimized to ensure adequate stabilization without causing undesirable toxicity or altering the release profile [7].

Drug–lipid compatibility is another critical consideration, as the physicochemical properties of the drug such as lipophilicity (log P value), molecular weight, and melting point influence its solubility within the lipid matrix and overall encapsulation efficiency. Hydrophobic drugs typically exhibit higher entrapment in SLNs, whereas hydrophilic drugs may require additional formulation strategies, such as double emulsion (w/o/w) techniques, ion pairing, or surface adsorption approaches. The drug-to-lipid ratio also impacts nanoparticle size, surface charge, and release kinetics. The production method significantly influences particle characteristics. High-pressure homogenization (hot or cold) is the most widely employed technique due to its scalability and solvent-free nature. The hot method involves melting the lipid and emulsifying it with an aqueous surfactant solution at elevated temperatures before homogenization, while the cold method involves solidifying the lipid–drug mixture before mechanical size reduction, minimizing drug degradation for thermolabile compounds. Alternative methods such as solvent emulsification–evaporation, microemulsion-based techniques, ultrasonication, and spray drying offer specific advantages depending on drug stability, desired particle size, and cost constraints. Post-production processing is often necessary to enhance stability and handling. Lyophilization (freeze-drying) or spray drying can convert SLN dispersions into dry powders, improving shelf-life and facilitating incorporation into solid dosage forms. Cryoprotectants like mannitol, trehalose, or sucrose are typically added during freeze-drying to prevent particle aggregation [8].

Surface modification expands the functional capabilities of SLNs. Polyethylene glycol (PEG) coating, known as PEGylation, can reduce opsonization by the mononuclear phagocyte system, prolonging circulation time. Alternatively, functionalization with ligands such as folic acid, monoclonal antibodies, transferrin, or peptides enables active targeting to specific tissues or cellular receptors. Coating with mucoadhesive polymers like chitosan can improve residence time at mucosal sites and enhance absorption [9].

Applications in Drug Delivery

SLNs have been explored for a wide range of therapeutic applications due to their ability to improve solubility, stability, and bioavailability while enabling targeted and controlled release. In oral delivery,

SLNs can protect drugs from degradation in the gastrointestinal tract and enhance absorption through lymphatic transport. For instance, oral SLNs of curcumin and resveratrol have shown improved bioavailability and antioxidant activity [10].

In parenteral delivery, SLNs offer a sustained release profile and reduced systemic toxicity for anticancer agents like doxorubicin and paclitaxel. The use of PEGylated SLNs can prolong circulation time, enhancing tumor accumulation via the enhanced permeability and retention (EPR) effect. For transdermal delivery, SLNs can enhance skin penetration and provide localized drug release. Drugs like diclofenac and ketoconazole have been formulated into SLN-based gels for improved therapeutic outcomes. In ocular delivery, SLNs provide prolonged precorneal residence time and sustained drug release, as demonstrated in formulations for drugs such as timolol maleate and dexamethasone. In pulmonary delivery, SLNs can be engineered as inhalable powders or aerosols for local and systemic treatment, including for antibiotics and anticancer agents. SLNs are also increasingly applied in gene delivery, where cationic lipids in the SLN structure can complex with nucleic acids for targeted intracellular delivery [11,12].

Future Perspectives

While SLNs have demonstrated significant promise, challenges such as limited drug loading, burst release, and instability due to lipid polymorphic transitions remain to be addressed. Emerging approaches like nanostructured lipid carriers (NLCs)—which incorporate a mixture of solid and liquid lipids—offer higher drug loading and reduced expulsion during storage. Hybrid lipid–polymer nanoparticles combine the mechanical stability of polymers with the biocompatibility of lipids, enabling more precise release profiles. Advances in stimuli-responsive SLNs that release their payload in response to pH changes, temperature shifts, or enzymatic activity are particularly promising for targeted cancer therapy. Ligand-targeted SLNs conjugated with antibodies, peptides, or small molecules can improve tissue specificity, thereby reducing off-target effects. From a manufacturing standpoint, the adoption of green and continuous manufacturing techniques such as supercritical fluid technology can minimize solvent residues and energy consumption, aligning with sustainability goals. Artificial intelligence and computational modeling can further streamline SLN formulation by predicting drug–lipid compatibility and optimizing particle characteristics.

CONCLUSION

Solid lipid nanoparticles have evolved into a multifunctional platform for targeted and controlled drug delivery, offering advantages such as biocompatibility, scalability, and versatility in encapsulating diverse drug molecules. Their capacity to enhance bioavailability, protect labile compounds, and enable sustained release makes them suitable for multiple administration routes. Continued research into hybrid systems, stimuli-responsive designs, and scalable, eco-friendly production methods will be critical for overcoming current limitations. With these innovations, SLNs are poised to play an increasingly important role in the delivery of next-generation therapeutics, bridging the gap between laboratory research and clinical application.

REFERENCES

1. Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS. A Recent Update: Solid Lipid Nanoparticles for Effective Drug Delivery. Adv Pharm Bull. 2022 Jan;12(1):17-33.
2. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol. 2007 Feb;18(1):26-30.
3. Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development. ACS Mater Au. 2023 Aug 21;3(6):600-619.
4. Viegas C, Patrício AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review. Pharmaceutics. 2023; 15(6):1593.
5. Muller R.H., Shegokar R., Keck C.M. 20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications. Curr. Drug Discov. Technol. 2011;8:207–227.
6. Durán-Lobato M., Enguix-González A., Fernández-Arévalo M., Martín-Banderas L. Statistical analysis of solid lipid nanoparticles produced by high-pressure homogenization: A practical prediction approach. J. Nanoparticle Res. 2013;15:1–14.
7. Parhi R., Suresh P. Preparation and Characterization of Solid Lipid Nanoparticles—A Review. Curr. Drug Discov. Technol. 2012;9:2–16.
8. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur. J. Pharm. Biopharm. 2000;50:161–177.
9. Sawant K., Dodiya S. Recent Advances and Patents on Solid Lipid Nanoparticles. Recent Pat. Drug Deliv. Formul. 2008;2:120–135.

10. Akbari J., Saeedi M., Ahmadi F., Hashemi S.M.H., Babaei A., Yaddollahi S., Rostamkalaei S.S., Asare-Addo K., Nokhodchi A. Solid lipid nanoparticles and nanostructured lipid carriers: A review of the methods of manufacture and routes of administration. Pharm. Dev. Technol. 2022;27:1–53.
11. Pardeshi C., Rajput P., Belgamwar V., Tekade A., Patil G., Chaudhary K., Sonje A. Solid lipid based nanocarriers: An overview. Acta Pharm. 2012;62:433–472.
12. Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, Abraham MC, Kolimi P, Nyavanandi D, Dyawanapelly S. Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles. Pharmaceutics. 2022 Sep 6;14(9):1886. doi: 10.3390/pharmaceutics14091886. PMID: 36145632; PMCID: PMC9503303.